Built for accurate GLP-1 cycle planning
To address protopathic bias, outcomes occurring within 3 months after drug initiation were not considered
This overlap in symptoms creates a safety concern, especially in social situations where others might attribute concerning symptoms to alcohol consumption rather than recognizing a medical emergency
Anyone claiming that BPC-157 is a 'fat-burning peptide' is either misinformed or, frankly, being misleading
Determination of vesicle size, polydispersity index, and zeta-potential The average particle size, polydispersity index (PDI), and zeta potential of the fabricated ivermectin nanoformulations were determined using a Malvern Zetasizer Nano series ZS instrument (Malvern Instruments, Malvern, UK) after appropriate dilution at room temperature 37
Ethics declarations Competing interests Institut Curie filed a patent application (PCT/EP2025/051999) related to lipid degraders to induce ferroptosis in cancer